Literature DB >> 30871582

Correction to: The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis.

Alessandro Conforti1, Sandro C Esteves2, Francesca Di Rella3, Ida Strina4, Pasquale De Rosa4, Alessia Fiorenza5, Fulvio Zullo4, Giuseppe De Placido4, Carlo Alviggi4,6.   

Abstract

.

Entities:  

Year:  2019        PMID: 30871582      PMCID: PMC6419373          DOI: 10.1186/s12958-019-0475-x

Source DB:  PubMed          Journal:  Reprod Biol Endocrinol        ISSN: 1477-7827            Impact factor:   5.211


× No keyword cloud information.
Correction to: Reproductive Biology and Endocrinology (2019) 17:18 https://doi.org/10.1186/s12958-019-0460-4 Following publication of the original article [1], the authors would like to apologize for an error in Fig. 2 describing clinical pregnancy rate comparison between treatment arms. The authors would like to reassure the readers that this minor type error does not affect any other content and the main findings of the article. The correct figure is presented below.
Fig. 2

Forest plot of odds ratio for the clinical pregnancy rate in rFSH + rLH versus rFSH alone treatment

Forest plot of odds ratio for the clinical pregnancy rate in rFSH + rLH versus rFSH alone treatment
  1 in total

1.  The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis.

Authors:  Alessandro Conforti; Sandro C Esteves; Francesca Di Rella; Ida Strina; Pasquale De Rosa; Alessia Fiorenza; Fulvio Zullo; Giuseppe De Placido; Carlo Alviggi
Journal:  Reprod Biol Endocrinol       Date:  2019-02-06       Impact factor: 5.211

  1 in total
  1 in total

1.  A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.

Authors:  Ming-Jer Chen; Yu-Chiao Yi; Hwa-Fen Guu; Ya-Fang Chen; Hsiao-Fan Kung; Jui-Chun Chang; Shih-Ting Chuan; Li-Yu Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-15       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.